(Q48005178)

7 February 2018

title

Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment (English)

1 reference

7 February 2018

author name string

B Strober

1

1 reference

7 February 2018

M Buonanno

2

1 reference

7 February 2018

J D Clark

3

1 reference

7 February 2018

T Kawabata

4

1 reference

7 February 2018

H Tan

5

1 reference

7 February 2018

R Wolk

6

1 reference

7 February 2018

H Valdez

7

1 reference

7 February 2018

R G Langley

8

1 reference

7 February 2018

J Harness

9

1 reference

7 February 2018

A Menter

10

1 reference

7 February 2018

K Papp

11

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 November 2013

1 reference

7 February 2018

British Journal of Dermatology

published in

1 reference

7 February 2018

volume

169

1 reference

7 February 2018

issue

5

1 reference

7 February 2018

page(s)

992-999

1 reference

7 February 2018

New insights in the immunologic basis of psoriasis

cites work

1 reference

Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study

21 January 2018

1 reference

Targeting the Jak/STAT pathway for immunosuppression

21 January 2018

1 reference

Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.

21 January 2018

1 reference

Regulation of JAK-STAT signalling in the immune system

21 January 2018

1 reference

JAKs and STATs in immunity, immunodeficiency, and cancer

21 January 2018

1 reference

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

21 January 2018

1 reference

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study

21 January 2018

1 reference

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

21 January 2018

1 reference

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

21 January 2018

1 reference

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats.

21 January 2018

1 reference

Quantitative analysis of mechanisms that govern red blood cell age structure and dynamics during anaemia

21 January 2018

1 reference

Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis

21 January 2018

1 reference

Erythroid disturbances before and after treatment of Portuguese psoriasis vulgaris patients: a cross-sectional and longitudinal study

21 January 2018

1 reference

Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop

21 January 2018

1 reference

IL-6 plays an essential role in neutrophilia under inflammation.

21 January 2018

1 reference

Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach.

21 January 2018

1 reference

Developmental defects of lymphoid cells in Jak3 kinase-deficient mice.

21 January 2018

1 reference

The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia

21 January 2018

1 reference

Intracellular signal transduction in eosinophils and its clinical significance

21 January 2018

1 reference

21 January 2018

IL-5 and eosinophilia.

1 reference

Interleukin-5 and IL-5 receptor in health and diseases

21 January 2018

1 reference

Interleukin 9 promotes influx and local maturation of eosinophils

21 January 2018

1 reference

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJD.12517

1 reference

7 February 2018

1 reference

7 February 2018